DENOVO BIOPHARMA LLC

ACTIVE

10240 Science Center Dr Ste 120, San Diego, California, 美国www.denovobiopharma.com/en/index_English.htmlSubsidiary11–50 名员工成立于: 2011-01-01

概览

试验阶段分布

阶段

试验数

占比

1 期

36.4%

2 期

36.4%

3 期

27.3%

试验状态分布

已完成

72.7%

终止

22.7%

撤回

4.5%

药物批准

暂无批准数据

资讯

Denovo Biopharma Out-Licenses Biomarker-Guided Depression Drug DB104 to Taiwan Partner

- Denovo Biopharma has granted exclusive rights to develop and commercialize DB104 (liafensine) in Taiwan to Chuang Yi Global Asset Management Co., Ltd. - DB104 is a first-in-class triple reuptake inhibitor that targets serotonin, norepinephrine, and dopamine transporters for treatment-resistant depression. - The drug utilizes a novel pharmacogenomic biomarker within the ANK3 gene discovered through AI and whole genome scanning to predict efficacy. - Taiwan currently has no approved antidepressants for treatment-resistant depression, representing a significant unmet medical need in the region.

Jun 23, 2025

返回机构列表

DENOVO BIOPHARMA LLC

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（22）

A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1

Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

A Study of LY2140023 in Healthy Participants

A Study of LY2140023 in Healthy Participants

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

A Study of LY2140023 in Healthy Participants

A Study of LY2140023 in Healthy Males and Females

药物批准

资讯

Denovo Biopharma Out-Licenses Biomarker-Guided Depression Drug DB104 to Taiwan Partner